Tesamorelin: products and studies

Start with the indication

Egrifta SV and Egrifta WR contain tesamorelin. Their FDA indication is excess abdominal fat in adults with HIV and lipodystrophy. Neither is indicated for general weight loss. Long-term cardiovascular safety remains unestablished.

Separate formulation from cadence

Both labels describe once-daily subcutaneous injections. SV is supplied in a 2 mg single-dose vial. WR is supplied in an 11.6 mg single-patient-use vial that provides seven daily doses. WR does not mean a weekly injection.

The products differ in prescribed dose, preparation, and storage. They are not substitutable. A vial strength is not the amount prescribed for an injection. This reference does not provide preparation instructions.

Read the trial in context

Falutz and colleagues studied daily subcutaneous tesamorelin versus placebo for 26 weeks in 412 adults with HIV and abdominal fat accumulation. The primary outcome was change in visceral fat on CT. The trial supports a population-specific visceral-fat claim. It does not establish general weight-loss effectiveness or prevention of heart attacks. The original trial formulation must not be treated as interchangeable with either current product.

Record the clinician-directed plan

Keep the exact product, vial strength, prescribed amount and unit, route, schedule, start date, and actual administration dates together. Record the treatment goal and clinician-arranged follow-up. The labels call for IGF-1 monitoring and glucose evaluation before and during treatment. Record results and reported symptoms for that review. A product change needs a product-specific prescription and pharmacist instructions.